ph触发动态无载体纳米药物自组装的达沙替尼和氯苯,具有精确肿瘤靶向治疗的潜力

IF 2.7 4区 医学 Q2 PHARMACOLOGY & PHARMACY Journal of Pharmaceutical Innovation Pub Date : 2023-11-30 DOI:10.1007/s12247-023-09801-x
Yuanpeng Wang, Chensong Zhang, Shaobo Zhou, Liang Chu, Wei Fang, Jiachi Ma
{"title":"ph触发动态无载体纳米药物自组装的达沙替尼和氯苯,具有精确肿瘤靶向治疗的潜力","authors":"Yuanpeng Wang, Chensong Zhang, Shaobo Zhou, Liang Chu, Wei Fang, Jiachi Ma","doi":"10.1007/s12247-023-09801-x","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Dynamic carrier-free theranostic nanodrugs are in great demand, owing to their extraordinary high drug loading, enhanced targeting therapy, and panoramic tracking of the drug behaviors. Herein, this work highlights a successful development of pH-triggered dynamic carrier-free nanodrugs for precise tumoral targeting theragnostic, which are established through self-assembly between dasatinib (DAS) and chlorambucil (CLB).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The study has proved the structure, change in particle size and zeta potential, fluorescence transition, cellular uptake, cytotoxicity as well as biosafety of the carrier-free nanodrugs. The nanodrugs are characterized by Fourier transform infrared spectroscopy, <sup>1</sup>H nuclear magnetic resonance, X-ray diffraction, Dynamic light scattering, and Microplate reader. Cellular uptake and cytotoxicity assay are conducted for free drugs and their nanodrugs using tumor cell lines including A549, HepG2, K562, and THP1. ICR mice are applied to evaluate the biosafety of nanodrugs.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The introduction of CLB into DAS nanoparticles can successfully redshift the emission wavelength from 420 to 810 nm. Moreover, the nanodrugs exhibit a dynamic fluorescence intensity conversion via tumoral intracellular gradual quenching of Aggregation-induced emission (AIE). This characteristic is beneficial to the precise monitoring of tumoral intracellular drug behaviors. Furthermore, the nanodrugs show a small-to-large size transition from 175 nm to more than 500 nm in 12 h and surficial charge reversal from −2.3 mV to more than 0.2 mV by protonation at tumoral pHs. These superior properties facilitate the improved cellular uptake and synergistic cytotoxicity on various types of tumor cells.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The study shows that nanodrugs made of DAS and CLB that can self-assemble without carriers under different pH levels may be ready for testing in tumor targeting, and might someday be helpful for diagnosis and treatment in the future.</p>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":" 9","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"pH-Triggered Dynamic Carrier-Free Nanodrugs Self-Assembled from Dasatinib and Chlorambucil with a Potential for Precise Tumoral Targeting Theranostic\",\"authors\":\"Yuanpeng Wang, Chensong Zhang, Shaobo Zhou, Liang Chu, Wei Fang, Jiachi Ma\",\"doi\":\"10.1007/s12247-023-09801-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h3 data-test=\\\"abstract-sub-heading\\\">Purpose</h3><p>Dynamic carrier-free theranostic nanodrugs are in great demand, owing to their extraordinary high drug loading, enhanced targeting therapy, and panoramic tracking of the drug behaviors. Herein, this work highlights a successful development of pH-triggered dynamic carrier-free nanodrugs for precise tumoral targeting theragnostic, which are established through self-assembly between dasatinib (DAS) and chlorambucil (CLB).</p><h3 data-test=\\\"abstract-sub-heading\\\">Methods</h3><p>The study has proved the structure, change in particle size and zeta potential, fluorescence transition, cellular uptake, cytotoxicity as well as biosafety of the carrier-free nanodrugs. The nanodrugs are characterized by Fourier transform infrared spectroscopy, <sup>1</sup>H nuclear magnetic resonance, X-ray diffraction, Dynamic light scattering, and Microplate reader. Cellular uptake and cytotoxicity assay are conducted for free drugs and their nanodrugs using tumor cell lines including A549, HepG2, K562, and THP1. ICR mice are applied to evaluate the biosafety of nanodrugs.</p><h3 data-test=\\\"abstract-sub-heading\\\">Results</h3><p>The introduction of CLB into DAS nanoparticles can successfully redshift the emission wavelength from 420 to 810 nm. Moreover, the nanodrugs exhibit a dynamic fluorescence intensity conversion via tumoral intracellular gradual quenching of Aggregation-induced emission (AIE). This characteristic is beneficial to the precise monitoring of tumoral intracellular drug behaviors. Furthermore, the nanodrugs show a small-to-large size transition from 175 nm to more than 500 nm in 12 h and surficial charge reversal from −2.3 mV to more than 0.2 mV by protonation at tumoral pHs. These superior properties facilitate the improved cellular uptake and synergistic cytotoxicity on various types of tumor cells.</p><h3 data-test=\\\"abstract-sub-heading\\\">Conclusion</h3><p>The study shows that nanodrugs made of DAS and CLB that can self-assemble without carriers under different pH levels may be ready for testing in tumor targeting, and might someday be helpful for diagnosis and treatment in the future.</p>\",\"PeriodicalId\":656,\"journal\":{\"name\":\"Journal of Pharmaceutical Innovation\",\"volume\":\" 9\",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2023-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmaceutical Innovation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12247-023-09801-x\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Innovation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12247-023-09801-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的动态无载体治疗纳米药物由于其极高的载药量、增强的靶向治疗和药物行为的全景跟踪而受到广泛的需求。在这里,这项工作强调了ph触发的动态无载体纳米药物的成功开发,用于精确的肿瘤靶向治疗,这些药物是通过达沙替尼(DAS)和氯苯(CLB)之间的自组装建立的。方法研究无载体纳米药物的结构、粒径和zeta电位的变化、荧光跃迁、细胞摄取、细胞毒性和生物安全性。利用傅里叶变换红外光谱、1H核磁共振、x射线衍射、动态光散射和微孔板阅读器对纳米药物进行了表征。利用肿瘤细胞系A549、HepG2、K562和THP1对游离药物及其纳米药物进行细胞摄取和细胞毒性测定。应用ICR小鼠评价纳米药物的生物安全性。结果将CLB引入到DAS纳米粒子中,使发射波长从420 nm红移至810 nm。此外,纳米药物通过肿瘤细胞内聚集诱导发射(AIE)的逐渐猝灭表现出动态荧光强度转换。这一特点有利于肿瘤细胞内药物行为的精确监测。此外,纳米药物在12小时内从175 nm到超过500 nm的大小转变,表面电荷反转从- 2.3 mV到超过0.2 mV,在肿瘤ph下质子化。这些优越的性质有助于提高细胞摄取和对各种类型肿瘤细胞的协同细胞毒性。结论由DAS和CLB制备的纳米药物可以在不同的pH水平下无载体自组装,有望用于肿瘤靶向测试,并在未来的诊断和治疗中有所帮助。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
pH-Triggered Dynamic Carrier-Free Nanodrugs Self-Assembled from Dasatinib and Chlorambucil with a Potential for Precise Tumoral Targeting Theranostic

Purpose

Dynamic carrier-free theranostic nanodrugs are in great demand, owing to their extraordinary high drug loading, enhanced targeting therapy, and panoramic tracking of the drug behaviors. Herein, this work highlights a successful development of pH-triggered dynamic carrier-free nanodrugs for precise tumoral targeting theragnostic, which are established through self-assembly between dasatinib (DAS) and chlorambucil (CLB).

Methods

The study has proved the structure, change in particle size and zeta potential, fluorescence transition, cellular uptake, cytotoxicity as well as biosafety of the carrier-free nanodrugs. The nanodrugs are characterized by Fourier transform infrared spectroscopy, 1H nuclear magnetic resonance, X-ray diffraction, Dynamic light scattering, and Microplate reader. Cellular uptake and cytotoxicity assay are conducted for free drugs and their nanodrugs using tumor cell lines including A549, HepG2, K562, and THP1. ICR mice are applied to evaluate the biosafety of nanodrugs.

Results

The introduction of CLB into DAS nanoparticles can successfully redshift the emission wavelength from 420 to 810 nm. Moreover, the nanodrugs exhibit a dynamic fluorescence intensity conversion via tumoral intracellular gradual quenching of Aggregation-induced emission (AIE). This characteristic is beneficial to the precise monitoring of tumoral intracellular drug behaviors. Furthermore, the nanodrugs show a small-to-large size transition from 175 nm to more than 500 nm in 12 h and surficial charge reversal from −2.3 mV to more than 0.2 mV by protonation at tumoral pHs. These superior properties facilitate the improved cellular uptake and synergistic cytotoxicity on various types of tumor cells.

Conclusion

The study shows that nanodrugs made of DAS and CLB that can self-assemble without carriers under different pH levels may be ready for testing in tumor targeting, and might someday be helpful for diagnosis and treatment in the future.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Pharmaceutical Innovation
Journal of Pharmaceutical Innovation PHARMACOLOGY & PHARMACY-
CiteScore
3.70
自引率
3.80%
发文量
90
审稿时长
>12 weeks
期刊介绍: The Journal of Pharmaceutical Innovation (JPI), is an international, multidisciplinary peer-reviewed scientific journal dedicated to publishing high quality papers emphasizing innovative research and applied technologies within the pharmaceutical and biotechnology industries. JPI''s goal is to be the premier communication vehicle for the critical body of knowledge that is needed for scientific evolution and technical innovation, from R&D to market. Topics will fall under the following categories: Materials science, Product design, Process design, optimization, automation and control, Facilities; Information management, Regulatory policy and strategy, Supply chain developments , Education and professional development, Journal of Pharmaceutical Innovation publishes four issues a year.
期刊最新文献
An Analysis of FDA Warning Letter Citations from 2019-2023 Ocular Delivery of Itraconazole Loaded Leciplex to Treat Fungal Infection Formulation, Evaluation, Factorial Optimization, and In-Silico Study of Eplerenone Loaded Pectin Nanoparticles: A New Approach to the Proliferation of Human Skin Fibroblasts for Wound Healing A Novel Mesalamine Loaded Hybrid Nanoparticle-in-Microparticle for Colon Targeting: In-vitro and In-vivo Investigations Editorial: Innovation Exists in Many Areas of Pharmaceutical Development and Commercialization
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1